Document:

WWW.EXFILE.COM -- MATRITECH FORM 8-K -- EXHIBIT 4.9 -- 14850

    EXHIBIT
      4.9

    

    AMENDED
      AND RESTATED CONTINGENT LICENSE AGREEMENT

    

    This
      AMENDED AND RESTATED CONTINGENT LICENSE AGREEMENT (this “Agreement”)
      is
      made as of the 22nd day of January, 2007 (the “Effective
      Date”),
      by
      and among MATRITECH, INC. a corporation organized under the laws of the State
      of
      Delaware (the “Licensor”),
      and
SDS
      CAPITAL GROUP SPC, LTD. (the “Licensee”),
      as
      collateral agent for the holders (the “Holders”)
      of the
      Series A Notes and the Series B Notes (as defined below) (in such capacity,
      the
“Collateral
      Agent”).

    

    WHEREAS,
      the Licensor and certain Holders entered a certain Securities Purchase
      Agreement, dated as of January 13, 2006 (as the same may be amended, restated,
      modified, supplemented and/or replaced from time to time, the “Series
      A Purchase Agreement”),
      pursuant to which the Licensor issued its 15% Secured Convertible Promissory
      Notes to such Holders (the “Series
      A Note Holders”)
      in the
      original aggregate principal amount of $6,997,960 (as the same may be amended,
      restated, modified, supplemented and/or replaced from time to time, the
“Series
      A Notes”);
      

    

    WHEREAS,
      in order to induce the Series A Note Holders to purchase the Series A Notes,
      the
      Licensor executed and delivered to the Collateral Agent a Security Agreement,
      dated as of January 13, 2006 (as heretofore amended, the “Existing
      Security Agreement”),
      pursuant to which the Licensor granted to the Collateral Agent, for the benefit
      of itself and the Series A Note Holders, a perfected security interest in
      certain property of the Licensor to secure the prompt payment, performance
      and
      discharge in full of all of Borrower’s obligations under the Series A
      Notes;

    

    WHEREAS,
      in connection with the Series A Purchase Agreement, concurrently therewith,
      the
      Licensor and the Collateral Agent entered into a Contingent License Agreement,
      dated as of January 13, 2006 (as heretofore amended, the “Existing
      Contingent License Agreement”),
      pursuant to which the Licensor granted to the Collateral Agent, for the benefit
      of itself and the Series A Note Holders, a contingent license under the
      Matritech Patent Rights, the Matritech Trademark Rights and the MIT Patent
      Rights (each as defined therein) on the terms and conditions set forth
      therein;

    

    WHEREAS,
      concurrently herewith, the Licensor and certain Holders are entering into a
      Securities Purchase Agreement, dated as of the date hereof (as the same may
      be
      amended, restated, modified, supplemented and/or replaced from time to time,
      the
“Series
      B Purchase Agreement”
and,
      together with the Series A Purchase Agreement, the “Purchase
      Agreements”),
      pursuant to which the Licensor is issuing its Series B 15% Secured Convertible
      Promissory Notes to such Holders (the “Series
      B Note Holders”
and,
      together with the Series A Note Holders, the “Holders”)
      in the
      original aggregate principal amount of up to $4,500,000 (as the same may be
      amended, restated, modified, supplemented and/or replaced from time to time,
      the
“Series
      B Notes”
and,
      together with the Series A Notes, the “Notes”);

    

    WHEREAS,
      concurrently herewith, the holders of a majority of outstanding principal
      balance of the Series A Notes have consented to the issuance of the Series
      B
      Notes and directed

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    the
      Collateral Agent to amend and restate the Existing Security Agreement and
      Existing Contingent License Agreement to enable the Series B Note Holders to
      have a pari
      passu
      position
      with the Series A Note Holders as to the security interest and license granted
      under such agreements;

    

    WHEREAS,
      in connection with the Series B Purchase Agreement, concurrently therewith,
      the
      Licensor and the Collateral Agent are amending and restating the Existing
      Security Agreement (as same may be amended, restated, modified, supplemented
      and/or replaced from time to time, the “Security
      Agreement”)
      in
      order to grant to the Collateral Agent, for the benefit of itself and of the
      Holders, a perfected security interest in certain property of Licensor
to
      secure
      the prompt payment, performance and discharge in full of all of Licensor’s
      obligations under the Notes, all on the terms and conditions set forth
      therein;

    

    WHEREAS,
      Licensor is the owner of the Matritech Patent Rights and Matritech
      Trademark Rights
      (each as
      defined below) and has the right to sublicense the MIT Patent Rights (as defined
      below); and

    

    WHEREAS,
      in order to induce the Series B Note Holders to purchase the Series B Notes
      pursuant to the Series B Purchase Agreement, the Licensor agrees to amend and
      restate the Existing Contingent License Agreement in order to grant to Licensee,
      for the benefit of itself and the Holders, a contingent license under the
      Matritech Patent Rights, the Matritech Trademark Rights and the MIT Patent
      Rights on the terms and conditions set forth in this Agreement;

    

    NOW,
      THEREFORE, in consideration of the foregoing and the mutual covenants contained
      herein, and for other good and valuable consideration, the receipt and
      sufficiency of which are hereby acknowledged, the parties hereto agree to amend
      and restate the Existing Contingent License Agreement so that, as amended and
      restated, it reads in its entirety as provided herein:

    

    1.  Definitions.

     

    (a)  “Abbott
      License Agreement”
shall
      mean the license agreement entered into by and between Abbott Laboratories
      and
      Matritech, Inc., effective April 1, 2004.

     

    (b)  “Event
      of Default”
shall
      mean an Event of Default described in Sections A(i), (vi) and (vii) of Article
      (VI) of the Series A Notes or as described in Sections A(i), (vi) and (vii)
      of
      Article (VI) of the Series B Notes.

     

    (c)  “Expiration
      Date”
shall
      mean the earlier to occur of the date on which (i) on a country-by-country
      basis, the expiration of the last to expire of any Valid Claim included in
      the
      Matritech Patent Rights and the MIT Patent Rights in such country, (ii) all
      principal, premium, if any, interest on the Notes, and any other amounts payable
      pursuant to the terms of the Notes have been paid in full, or (iii) receipt
      of
      payments by the Licensee on net profits on the sales of Licensed Products
      hereunder that equal the unpaid balance of all principal, premium, if any,
      interest on the Notes, and any other amounts payable pursuant to the terms
      of
      the Notes.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (d)  “Field”
shall
      mean the field of bladder cancer detection in humans.

     

    (e)  “License
      Agreements”
shall
      mean the MIT License Agreement and the Abbott License Agreement.

     

    (f)  “Licensed
      Products”
shall
      mean any human bladder cancer detection product, including without limitation
      the NMP22® BladderChek® Test and the NMP22® Test Kit, developed, marketed,
      and/or sold by Licensee.

     

    (g)  “License
      Term”
shall
      mean the period commencing on the effective date of an Event of Default and
      continuing until the Expiration Date.

     

    (h)  “Matritech
      Patent Rights”
shall
      mean the patent rights listed on Schedule
      A,
      and any
      continuation, continuation-in-part, divisional, reexamination, or reissue
      thereof, and any foreign counterpart patents and patent applications to any
      of
      the foregoing.

     

    (i)  “Matritech
      Trademark Rights”
shall
      means the trademark rights listed on Schedule
      B
      and the
      goodwill of the business symbolized thereby, and related registrations and
      applications for registration to any of the foregoing.

     

    (j)  “MIT
      License Agreement”
shall
      mean the license agreement entered into by and between Massachusetts Institute
      of Technology (“MIT”)
      and
      Matritech, Inc., effective December 14, 1987 attached hereto as Schedule
      F.

     

    (k)  “MIT
      Patent Rights”
shall
      mean the patent rights listed on Schedule
      C,
      and any
      continuation, continuation-in-part, divisional, reexamination, or reissue
      thereof, and any foreign counterpart patents and patent applications to any
      of
      the foregoing.

     

    (l)  “Permitted
      Amendment”
shall
      mean, with respect to an agreement to which Licensor is a party, any amendment,
      alteration, waiver or other change of any of the terms or conditions of such
      agreement in a manner that would not materially adversely affect Licensee’s
      rights or obligations provided under this Agreement with respect to such
      agreement.

     

    (m)  “Secured
      Obligations”
shall
      have the meaning set forth in the Security Agreement.

     

    (n)  “Territory”
shall
      mean the entire world.

     

    (o)  “Unotech
      Contract”
      shall
      mean the Contract and Manufacturing Arrangement entered into by and between
      Unotech Diagnostics, Inc. (“Unotech”)
      and
      Matritech, Inc., on March 22, 2001. 

     

    (p)  “Valid
      Claim”
shall
      mean a claim of any issued and unexpired patent within the Matritech Patent
      Rights and/or the MIT Patent Rights which has not lapsed, become abandoned
      or
      been held revoked, invalid, or unenforceable by a decision of a court or
      administrative or government authority or agency of competent jurisdiction
      from
      which no 

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    appeal
      can be or has been taken within the time allowed for such appeal, and which
      has
      not been admitted to be invalid or unenforceable through reissue, disclaimer
      or
      otherwise.

     

    2.  License
      Grants and Restrictions.

     

    (a)  Matritech
      Patent License Grant.
      Subject
      to (i) the terms and conditions set forth in this Agreement, (ii) any license
      rights granted to Unotech under the Unotech Contract, and (iii) any license
      rights, similar to those granted to Unotech under the Unotech Contract, granted
      to any third party manufacturer, Licensor hereby grants to Licensee, and
      Licensee hereby accepts, an exclusive, royalty-free, fully paid-up, right and
      license under the Matritech Patent Rights to make, have made, use, sell, have
      sold, offer for sale, have offered for sale, import and have imported Licensed
      Products in each case within the Field and within the Territory during the
      License Term. Licensee may sublicense, directly or indirectly (through multiple
      tiers), the rights granted to Licensee under this Section 2(a)
      to any
      entity
      or
      person. The
      license granted under this Section 2(a) shall
      terminate effective immediately as of the Expiration Date.

     

    (b)  MIT
      Patent Sublicense Grant.
      Subject
      to the terms and conditions set forth in this Agreement and the sections of
      the
      MIT License Agreement attached hereto as Schedule
      D,
      Licensor hereby grants to Licensee, and Licensee hereby accepts, an exclusive,
      royalty bearing, right and license under the MIT Patent Rights to make, have
      made, use, sell, have sold, offer for sale, have offered for sale, import and
      have imported Licensed Products in each case within the Field and within the
      Territory during the License Term. Licensee may sublicense, directly or
      indirectly (through multiple tiers), the rights granted to Licensee under this
      Section 2(b)
      to any
      entity or person. The
      license granted under this Section 2(b) shall
      terminate effective immediately as of the Expiration Date. 

     

    (i)  Licensee
      agrees to be bound by the obligations to MIT set forth in the sections of the
      MIT License Agreement attached hereto as Schedule
      D
      as if
      Licensee were a party to the MIT License Agreement.

     

    (c)  Matritech
      Trademark License Grant.
      

     

    (i)  Subject
      to the terms and conditions set forth in this Agreement, Licensor hereby grants
      to Licensee, and Licensee hereby accepts, an exclusive, royalty-free, fully
      paid-up, right and license under the Matritech Trademark Rights to
      use
      and display the Matritech
      Trademark Rights
      in any
      and all advertising and other promotional materials (whether in traditional
      print or electronic format) relating to the marketing, advertising, promotion,
      and/or selling of Licensed Products within the Field and within the Territory
      during the License Term. Licensee may sublicense, directly or indirectly
      (through multiple tiers), the rights granted to Licensee under this Section
      2(c)
      to any
      entity or person. The
      license granted under this Section 2(c) shall
      terminate effective immediately as of the Expiration Date. 

     

    (ii)  The
      Licensor and Licensee hereby acknowledge that the Matritech Trademark Rights
      have established goodwill, and acknowledge the importance of Licensor’s control
      over the quality of Licensee’s use thereof so as to preserve the 

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    continued
      validity of the Matritech Trademark Rights and to protect the goodwill
      associated therewith. Licensee agrees that the quality of the products and
      services provided by Licensee under the Matritech Trademark Rights shall equal
      or exceed the standard of quality heretofore established and maintained by
      Licensor with respect to the same or similar products and services. All goodwill
      resulting from Licensee’s use of the Matritech Trademark Rights shall inure to
      the benefit of Licensor. If Licensor determines that Licensee is using or
      displaying any Matritech Trademark Rights in a manner that is or may be
      detrimental to Licensor’s interest, Licensor may issue reasonable instructions
      to Licensee concerning the manner, if any, in which Licensee may continue to
      use
      such Matritech Trademark Rights. Licensee shall promptly comply with such
      instructions or cease the use or display of such Matritech Trademark
      Rights.

     

    (d)  Sublicenses.
      Licensee’s right to sublicense under Sections 2(a)
      through
2(c)
      hereunder shall be exclusive to it and may only be made during the License
      Term.
      Prior to any sublicense becoming effective, Licensee shall have furnished to
      Licensor a complete copy, including all exhibits and schedules thereto, of
      any
      sublicense granted by Licensee at least five (5) business days prior to the
      effective date of any such sublicense. Except as Licensor expressly agrees
      otherwise in writing, any sublicense granted by Licensee under this Section
      2(d)
      hereof
      shall be subject and subordinate to the terms of this Agreement, shall terminate
      not later than the Expiration Date and shall provide that all rights to the
      Matritech Patent Rights, MIT Patent Rights and Matritech Trademark Rights
      sublicensed by Licensee to its sublicensee hereunder shall revert exclusively
      to
      Licensor upon the Expiration Date automatically and without further action
      by
      either Licensor or Licensee.

     

    (e)  Limitation.
      The
      licenses granted to Licensee under this Agreement do not confer any right to
      practice the inventions covered by the claims of the Matritech Patent Rights
      and/or the MIT Patent Rights outside of the Field. Nothing in this Agreement
      shall prevent Licensor, directly or indirectly, from making, having made,
      selling, having sold, offering to sell, having offered for sale, importing,
      having imported, renting, and/or leasing any apparatus, systems or products
      outside of the Field which practice or embody, or are configured for use in
      practicing, the inventions covered by the claims of the Matritech Patent Rights
      and/or the MIT Patent Rights, or practicing any method covered by the claims
      of
      the Matritech Patent Rights and/or the MIT Patent Rights outside of the Field.
      Licensor reserves all rights not expressly granted herein.

     

    3.  Licensed
      Product Marking.
      To the
      extent required by applicable law, Licensee agrees to mark each Licensed Product
      and any and all associated materials with the proper patent numbers and patent
      and trademark notices, including without limitation, those patent numbers and
      notices that are listed on the NMP22® BladderChek® Test and the NMP22® Test Kit
      as of the Effective Date.

     

    4.  Confidentiality
      Obligations.

     

    (a)  “Confidential
      Information”
means,
      subject to the exceptions set forth in Section 4(c),
      any and
      all information included in or representing the Matritech Patent Rights

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    and/or
      the MIT Patent Rights and the existence of this Agreement, the terms and
      conditions of this Agreement, and Schedule
      F
      to this
      Agreement.

     

    (b)  The
      Licensee shall not disclose any Confidential Information to any third party
      nor
      use any Confidential Information for any purpose except as may be expressly
      authorized by the Licensor in writing. Notwithstanding the foregoing, the
      Licensee may disclose Confidential Information to the extent required by law
      or
      legal process, provided the Licensor is given reasonable prior written notice
      and a reasonable opportunity to intervene to protect its interests. Licensee
      hereby acknowledges that the MIT License Agreement has been filed with the
      U.S.
      Securities and Exchange Commission subject to a confidential treatment order
      with respect to certain portions thereof. The Licensee shall not disclose any
      Confidential Information pursuant to law or legal process without first
      notifying the Licensor and using reasonable efforts to minimize such disclosure
      and, in the case of the MIT License Agreement, to prevent the disclosure of
      the
      information subject to the aforesaid confidential treatment order, while such
      order is in effect. The obligations of this Section 4
      shall
      survive the expiration or termination of this License Agreement.

     

    (c)  Information
      will not be deemed Confidential Information hereunder if such information:
      (a)
      is known to the receiving party prior to receipt from the disclosing party
      directly or indirectly from a source other than one having an obligation of
      confidentiality to the disclosing party; (b) becomes known (independently of
      disclosure by the disclosing party) to the receiving party directly or
      indirectly from a source other than one having an obligation of confidentiality
      to the disclosing party; (c) becomes publicly known or otherwise ceases to
      be
      secret or confidential, except through a breach of this Agreement by the
      receiving party; or (d) is independently developed by the receiving
      party.

     

    (d)  Notwithstanding
      anything to the contrary in this Section 4,
      upon
      execution of this Agreement, the parties agree to execute the Notice of License
      Grant attached hereto as Schedule
      E,
      a copy
      of which may be recorded with the U.S. Patent and Trademark Office together
      with
Schedules A,
      B,
      and
C
      attached
      hereto.

     

    5.  Records
      and Audit Rights.
      

     

    (a)  Licensee
      shall maintain (and cause it sublicensees to maintain) complete and accurate
      records of any information which may be reasonably required by Licensor to
      determine whether Licensee is complying with the terms of this
      Agreement.

     

    (b)  For
      the
      sole purpose of determining whether Licensee is in compliance with the terms
      of
      this Agreement, Licensor shall have the right, at Licensor’s expense, to have an
      independent auditor conduct an inspection and audit of all the relevant
      accounting and sales books, records, agreements, and documents of Licensee,
      during regular business hours at Licensee’s offices and in such a manner as not
      to interfere unreasonably with Licensee’s normal business activities. In no
      event shall such audits be conducted hereunder more frequently than every twelve
      (12) months. Prior to commencing any such inspection and audit, any such
      independent auditor shall have entered into an agreement with Licensor which
      prohibits the disclosure of any information relating to Licensee to any party,
      including Licensor, except that

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    such
      auditor may issue a report to Licensor, the sole purpose of which shall be
      to
      report to Licensor whether Licensee is in compliance with the terms of this
      Agreement, including a summary of and sufficient detail regarding the scope,
      quality, and methodology of such compliance or lack thereof.

     

    6.  Term
      and Termination.
      

     

    (a)  The
      term
      of this Agreement (“Term”)
      shall
      commence on the Effective Date and continue until the Expiration
      Date.

     

    (b)  Upon
      termination or expiration of this Agreement and except as otherwise expressly
      provided herein, the licenses granted hereunder shall terminate, and any
      sublicenses granted by Licensee hereunder shall terminate
      simultaneously unless otherwise agreed to in writing by Licensor.
      

     

    7.  Prosecution,
      Maintenance and Enforcement.

     

    (a)  Prosecution
      and Maintenance.
      Licensor retains the sole right to prepare, file, prosecute, and maintain the
      patent applications and patents included in the Matritech Patent Rights and
      the
      trademark registrations and applications for registration included in the
Matritech
      Trademark Rights.
      No part
      of this Agreement shall be construed to require Licensor to file any patent
      or
      trademark application, secure any patent or trademark registration, provide
      copies of patent and/or trademark applications or patents and/or trademark
      registrations to Licensee or disclose any inventions described or claimed in
      such patents or patent applications. Subject to Section 7(a)(i),
      Licensor agrees to maintain the Matritech
      Patent Rights and/or Matritech Trademark Rights
      and
      Licensor shall not abandon, transfer or license any of the Matritech
      Patent Rights and/or Matritech Trademark Rights, in
      each
      case that cover the Licensed Products, without the prior written approval of
      the
      Licensee.

     

    (i)  Option
      of Licensee to Prosecute/Maintain.
      Licensor shall give reasonable notice to Licensee of any desire to cease
      prosecution and/or maintenance of any of the Matritech Patent Rights and/or
      Matritech Trademark Rights, in each case that cover the Licensed Products,
      on a
      country by country basis in the Territory. In the event that Licensee wishes
      Licensor to continue prosecution of any such Matritech Patent Rights and/or
      Matritech Trademark Rights, Licensee shall provide timely written instructions
      to Licensor and Licensor agrees to prosecute such Matritech Patent Rights and/or
      Matritech Trademark Rights at Licensor’s expense; provided,
      that
      Licensor shall not be obligated to prosecute any patent application and/or
      trademark application included in the Matritech Patent Rights and/or Matritech
      Trademark Rights in the event the Licensor determines, in its reasonable
      business judgment, that the prosecution of such application is no longer
      necessary or desirable in the conduct of its business as currently conducted
      or
      as currently proposed to be conducted. In the event that Licensee wishes
      Licensor to continue maintenance of any such Matritech Patent Rights and/or
      Matritech Trademark Rights, Licensee shall provide timely written instructions
      to Licensor and Licensor agrees to maintain such Matritech Patent Rights and/or
      Matritech Trademark Rights at Licensor’s expense.

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    (b)  Notice.
      In the
      event that Licensee becomes aware of any evidence that (i) any invention which
      is the subject of any patent applications and/or patents included in the
      Matritech Patent Rights infringes or is alleged to infringe any third party’s
      patent rights in any field of use, (ii) any patent applications and/or patents
      included in the Matritech Patent Rights is infringed or is alleged to be
      infringed by any third party in any field of use, (iii) any trademark included
      in the Matritech Trademark Rights infringes or is alleged to infringe any third
      party’s trademark rights in any field of use, or (iv) any trademark included in
      the Matritech Trademark Rights is infringed or is alleged to be infringed by
      any
      third party in any field of use, Licensee shall promptly notify Licensor in
      writing of the name and address of such third party, the alleged acts of
      infringement, and any available evidence of infringement. 

     

    (c)  Defense
      of Infringement Actions.
      Licensor shall defend any claim for patent or trademark infringement by a third
      party on account of the manufacture, sale, practice or use of any Licensed
      Products at its own expense, in its own name and entirely under its own
      direction and control, or settle any such action, proceeding or dispute by
      license. Notwithstanding the foregoing, no settlement of any such action or
      proceeding which restricts the scope, or adversely affects the enforceability,
      of the Matritech Patent Rights and/or Matritech Trademark Rights, in each case
      that cover the Licensed Products, may be entered into by Licensor without the
      prior written consent of Licensee, which consent shall not be unreasonably
      withheld, delayed or conditioned.

     

    (d)  Enforcement
      of Patent Rights.
      Licensor shall have the sole right, at its sole discretion, to bring any legal
      action for infringement of the Matritech Patent Rights and/or the Matritech
      Trademark Rights or to defend any counterclaim of invalidity or action of a
      third party for declaratory judgment of non-infringement or interference
      (“Enforcement
      Actions”),
      and
      Licensor may bring or defend and may settle any such Enforcement Actions solely
      at its own expense and through its counsel. Any recovery or proceeds of
      settlement or judgment in any Enforcement Actions brought or defended by
      Licensor under this Section 7(d)
      shall be
      shared in order, as follows: (A) Licensor shall recoup all of its reasonable
      out-of-pocket costs and expenses incurred in connection with such Enforcement
      Action; (B) any balance shall be applied toward the unpaid balance of all
      principal, premium, if any, interest on the Notes, and any other amounts payable
      pursuant to the terms of the Notes; and (C) any and all remaining balance shall
      be received by Licensor. If Licensor reasonably requests, Licensee agrees to
      become a party to and to participate in any such Enforcement Actions, and,
      without limiting the generality of the foregoing, Licensor may implead Licensee
      as a necessary party to any such legal action and Licensee agrees to consent
      to
      such joinder; provided, however that Licensee’s participation shall be at
      Licensor’s expense.

     

    (i)  Option
      of Licensee to Enforce.
      Licensor shall give reasonable notice to Licensee of any desire not to pursue
      any Enforcement Action contemplated by Section 7(d).
      In the
      event that Licensee wishes Licensor to pursue such Enforcement Action, Licensee
      shall provide timely written instructions to Licensor and Licensor agrees to
      pursue such Enforcement Action in its own name and Licensor and Licensee will
      share the costs and expenses of such Enforcement Action equally. In the event
      that Licensor recovers any damages or other sums in any such action, suit or
      proceeding or in settlement thereof, such damages or other sums recovered shall
      be shared in order, as

     

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    follows:
      (A) Licensee shall recoup all of its reasonable out-of-pocket costs and expenses
      incurred in connection with such Enforcement Action; (B) any balance shall
      be
      applied toward the unpaid balance of all principal, premium, if any, interest
      on
      the Notes, and any other amounts payable pursuant to the terms of the Notes;
      and
      (C) any and all remaining balance shall be received by Licensor.

     

    8.  Representations
      of Licensor.
      

     

    (a)  Licensor
      shall not amend, restate, alter, waive or otherwise change any of the terms
      and
      conditions of any License Agreement without the prior written approval of
      Licensee, other than pursuant to a Permitted Amendment.

     

    (b)  Licensor
      represents that, the Matritech Patent Rights, Matritech Trademark Rights, MIT
      Patent Rights, and the intellectual property that is the subject of the Abbott
      License Agreement, are the only intellectual property rights Licensor owns
      or
      has the right to use under any written license agreement that relate to the
      Licensed Products.

     

    9.  Laws
      and Regulations.
      Licensee agrees to cause any sublicensee to agree, and in the event that
      Licensee directly tests, manufactures, markets, packages, distributes or sells
      Licensed Products, then Licensee agrees on behalf of itself, for the benefit
      of
      Licensor to conduct all of its operations dealing with Licensed Products in
      accordance with all applicable laws, regulations and other requirements, which
      may be in effect from time to time, of all national governmental authorities,
      and of all states, municipalities and other political subdivisions and agencies
      thereof, including, without limitation the U.S. Food, Drug and Cosmetics Act,
      and the regulations and other requirements of the U.S. Food and Drug
      Administration and to exercise a reasonable standard of care in the testing,
      manufacture, marketing, packaging, distribution and sale of any Licensed
      Product.

     

    10.  Disclaimer.
      EXCEPT
      AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ITS
      DIRECTORS, OFFICERS, EMPLOYEES, OR AFFILIATES, MAKE ANY REPRESENTATIONS OR
      WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
      TO
      THE WARRANTY OF TITLE OR THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS
      FOR
      A PARTICULAR PURPOSE, OR NONINFRINGEMENT OR THE VALIDITY OF PATENT CLAIMS,
      ISSUED OR PENDING, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT
      DISCOVERABLE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION
      MADE OR WARRANTY GIVEN BY SUCH PARTY THAT THE EXERCISE BY THE OTHER PARTY OF
      THE
      LICENSE RIGHTS GRANTED HEREUNDER SHALL NOT INFRINGE ANY PATENT OF ANY THIRD
      PARTY.

     

    11.  Limitation
      of Liability.
      TO THE
      MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY,
      ITS
      DIRECTORS, OFFICERS, EMPLOYEES OR AFFILIATES BE LIABLE HEREUNDER FOR SPECIAL,
      INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE
      OR
      INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS 

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    OF
      WHETHER THE OTHER PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW,
      OR IN
      FACT SHALL KNOW, OF THE POSSIBILITY OF THE FOREGOING.

     

    12.  Section
      365(n) of the Bankruptcy Code.
      All
      rights and licenses granted by Licensor under or pursuant to this Agreement
      are,
      for all purposes of Section 365(n) of Title 11 of the United States Code
      (“Title
      11”),
      licenses of rights to “intellectual
      property”
as
      defined in Title 11. Licensor agrees that, in the event of the commencement
      of
      bankruptcy proceedings by or against Licensor under Title 11, Licensee, as
      licensee of such rights under this Agreement, shall retain and may fully
      exercise all of its rights under this Agreement (including the licenses granted
      hereunder) and all of its rights and elections under Title 11. Without limiting
      the generality of the foregoing, if this Agreement is terminated under any
      applicable insolvency law, or Licensor or an administrator refuses to further
      perform this Agreement (or any of Licensor’s obligations hereunder) under any
      applicable insolvency law, then Licensee may elect to retain all of its license
      rights under this Agreement (including without limitation the rights described
      in Section 2
      herein)
      for the remainder of the term of this Agreement. 

     

    13.  Relationship
      of Parties.
      Nothing
      herein shall be construed to create any partnership, joint venture, agency
      or
      similar relationship, or to subject the parties to any implied duties or
      obligations respecting the conduct of their affairs which are not expressly
      stated herein. Neither party shall have any right or authority to assume or
      create any obligation or responsibility, either express or implied, on behalf
      of
      or in the name of the other party, or to bind the other party in any matter
      or
      thing whatsoever.

     

    14.  Entire
      Agreement.
      Each
      party acknowledges that it has read this Agreement, fully understands it, and
      agrees to be bound by its terms and further agrees that it is the complete
      and
      exclusive statement of the agreement between the parties, which supersedes
      and
      merges all prior proposals, understandings and all other agreements, oral and
      written between the parties relating to the subject matter of this Agreement.
      This Agreement cannot be modified or altered except by a written instrument
      duly
      executed by the Licensor and the Collateral Agent and consented to by both
      (i)
      the holders of at least a majority of the outstanding principal balance on
      the
      Series A Notes and (ii) the holders of at least a majority of the outstanding
      principal balance on the Series B Notes. The failure of either party to exercise
      in any respect any right provided for herein shall not be deemed a waiver of
      any
      right hereunder.

     

    15.  Severability.
      If any
      provision of this Agreement shall be held to be invalid, illegal or
      unenforceable, the validity, legality and enforceability of the remaining
      provisions shall in no way be affected or impaired thereby. Further, the
      provision that is held to be invalid, illegal or unenforceable shall remain
      in
      effect as far as possible in accordance with the intention of the
      parties.

     

    16.  Governing
      Law.
      This
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of Delaware applicable to contracts made and to be performed in the State
      of Delaware.

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    17.  Binding
      Effect and Assignment.
      This
      Agreement shall be binding upon and inure to the benefit of the parties hereto
      and their respective heirs, executors, administrators, legal representatives,
      successors and permitted assigns. The Licensee may assign this Agreement without
      restriction, without the consent of the Licensor, and without any other
      restriction; and such assignee shall have all of the rights, privileges and
      benefits of this Agreement without the need to take any further action.

     

    18.  Notices.
      Any
      notice contemplated herein or required or permitted to be given hereunder shall
      be made in the manner set forth in either the Series A Purchase Agreement or
      the
      Series B Purchase Agreement, as applicable, and delivered, in the case of
      Licensee, at the addresses set forth on the signature pages to the Purchase
      Agreements, or to such other address as any party hereto may have last specified
      by written notice to the other party or parties.

     

    [Remainder
      of Page Intentionally Left Blank.]

    

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
      in
      duplicate by their duly authorized representatives as an instrument under seal
      as of the date first above written.

    

    LICENSOR

    

    MATRITECH,
      INC.

    

    

    By:
      /s/
      Stephen D.
      Chubb                           

    Name: Stephen
      D. Chubb

    Title: Chief
      Executive Officer

    

    

    

    

    LICENSEE

    

    SDS
      CAPITAL GROUP SPC, LTD.,

    as
      Collateral Agent 

    

    

    By:
      /s/
      Steve
      Derby                                     

    Name:
      Steve Derby 

    Title:
      Director

    

    
 

     

     

     

    

 

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    Schedule
      A

    

    MATRITECH
      PATENT RIGHTS

    A.           
      U.S.
      Patent Rights

    U.S.
      Patent No. 5,989,826

    U.S.
      Patent No. 6,162,608

    U.S.
      Patent No. 6,410,247

    U.S.
      Patent No. 6,740,494

    U.S.
      Patent No. 5,965,376

    U.S.
      Patent No. 5,783,403

    U.S.
      Patent No. 5,882,876

    U.S.
      Patent No. 5,698,439

    U.S.
      Patent No. 5,686,562

    U.S.
      Patent No. 5,780,596

    

    B.           
      Foreign
      Patent Rights

    Australian
      Patent No. 658,257

    Canadian
      Patent No. 2,122,473

    European
      Patent No. 642668 (validated in Austria, Belgium, France, Germany, Italy,
      Ireland, Luxembourg, the Netherlands, Spain, and the United
      Kingdom)

    Japanese
      Patent No. 3,190,042

    Australian
      Patent No. 681,855

    European
      Patent No. 0647270 (validated in Belgium, France, Germany, Italy, Spain, and
      the
      United Kingdom)

    
 

     

     

    
 

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    Schedule
      B

    

    MATRITECH
      TRADEMARK RIGHTS

    

    A.           
      U.S.
      Trademark Rights

    NMP22®
-
      US Trademark Registration No. 1,956,141

    NMP22®
-
      US Trademark Registration No. 1,963,117

    BLADDERCHEK®
      - US Trademark Registration No. 2,811,238

    

    

    B.           
      Foreign
      Trademark Rights

    NMP22®
-
      EU Trademark Registration No. 66,399

    UNMP®
-
      JP Trademark Registration No. 3,332,669

    BLADDERCHEKTM
      - EU Trademark Application No. 2,648,772

    NMP22
      BLADDERCHEKTM - EU Trademark Application No. 4,240,636

    

    
 

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

    Schedule
      C

    

    MIT
      PATENT RIGHTS

    

    

    Foreign
      Patent Rights

    

    Canadian
      Patent No. 1,341,466

    
 

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

    Schedule
      D

    

    MIT
      PATENT LICENSE PROVISIONS

    

    Article
      V - Reports and Records

     

    5.1
      LICENSEE
      shall keep full, true and accurate books of account containing all particulars
      that may be necessary for the purpose of showing the amounts payable to M.I.T.
      hereunder. Said books of account shall be kept at LICENSEE's principal place
      of
      business or the principal place of business of the appropriate Division of
      LICENSEE to which this Agreement relates. Said books and the supporting data
      shall be open at all reasonable times for five (5) years following the end
      of
      the calendar year to which they pertain, to the inspection of M.I.T. or its
      agents for the purpose of verifying LICENSEE's royalty statement or compliance
      in other respects with this Agreement.

     

    Article
      VII - Termination

     

    7.6
      Upon
      termination of this Agreement for any reason during the exclusive period, any
      sublicensee not then in default shall have the right to seek a license from
      M.I.T.

     

    Article
      XV - Miscellaneous Provisions

    

    15.1
      This
      Agreement shall be construed, governed, interpreted and applied in accordance
      with the laws of the Commonwealth of Massachusetts, U.S.A., except that
      questions affecting the construction and effect of any patent shall be
      determined by the law of the country in which the patent was
      granted.

     

    15.2
      The
      parties hereto acknowledge that this Agreement sets forth the entire Agreement
      and understanding of the parties hereto as to the subject matter hereof, and
      shall not be subject to any change or modification except by the execution
      of a
      written instrument subscribed to by the parties hereto.

     

    15.3
      The
      provisions of this Agreement are severable, and in the event that any provision
      of this Agreement shall be determined to be invalid or unenforceable under
      any
      controlling body of law, such invalidity or unenforceability shall not in any
      way affect the validity or enforceability of the remaining provisions
      hereof.

     

    15.4
      LICENSEE
      agrees to mark the Licensed Products sold in the United States with all
      applicable United States patent numbers. All Licensed Products shipped to or
      sold in other countries shall be marked in such a manner as to conform with
      the
      patent laws and practice of the country of manufacture or sale.

     

    15.5
      The
      failure of either party to assert a right hereunder or to insist upon compliance
      with any term or condition of this Agreement shall not constitute a waiver
      of
      that right or excuse a similar subsequent failure to perform any such term
      or
      condition by the other party.

     

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    Schedule
      E

    

    NOTICE
      OF LICENSE GRANT

    

    WHEREAS,
      Matritech, Inc. (“Licensor”),
      a
      Delaware corporation having a principal place of business at 330 Nevada Street,
      Newton, MA 02460, is the owner of the patent rights listed in Schedule
      A
      attached
      hereto, is the licensee of the patent rights listed in Schedule
      B
      attached
      hereto (collectively, “Patent
      Rights”)
      and is
      the owner of the trademark rights listed in Schedule
      C
      attached
      hereto (“Trademark
      Rights”);
      and

    

    WHEREAS,
      Licensor has entered into an “Amended
      and Restated Contingent License Agreement”
(the
      “Agreement”)
      with
      SDS Capital Group SPC, Ltd., as collateral agent for the holders of certain
      notes (collectively, the “Licensee”)
      on or
      about January 22, 2007.

    

    NOW,
      THEREFORE,
      let it
      be known by those present that, in consideration of the mutual promises and
      covenants set forth in the Agreement, and for other good and valuable
      consideration, the receipt and sufficiency of which is hereby acknowledged,
      and
      subject to the terms and conditions of the Agreement, Licensor has granted
      to
      Licensee, certain license rights under the Patent Rights and Trademark Rights
      as
      set forth in the Agreement.

    

    IN
      WITNESS WHEREOF,
      the
      parties hereto have caused this document to be duly executed on the dates first
      set forth above.

    

    

    

    LICENSOR

    

    MATRITECH,
      INC.

    

    

    By:
      ______________________________

    Name:

    Title:

    

    

    

    LICENSEE

    

    SDS
      CAPITAL GROUP SPC, LTD.,

    as
      Collateral Agent

    

    

    By:
      ______________________________

    Name:

    Title:

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

     

    Schedule
      F

    

    COPY
      OF MIT LICENSE AGREEMENT

    

    
 

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
         

      

      
        18WWW.EXFILE.COM -- MATRITECH FORM 8-K -- EXHIBIT 4.10 -- 14850

    EXHIBIT
      4.10

    

    AMENDMENT

    TO

    CERTIFICATE
      OF DESIGNATIONS, PREFERENCES AND RIGHTS OF 

    SERIES
      A
      CONVERTIBLE PREFERRED STOCK 

    OF

    MATRITECH,
      INC.

    

    FILED
      IN
      THE SECRETARY OF 

    STATE
      OF
      DELAWARE ON MARCH 4, 2005

    

    

    Matritech,
      Inc., a corporation organized and existing under and by virtue of the General
      Corporation Law of the State of Delaware (the “Corporation”),

    

    DOES
      HEREBY CERTIFY (Pursuant to Section 242 of the Delaware General Corporation
      Law):

    

    1. 
The
      name
      of the Corporation is Matritech, Inc.;

    

    2. 
That
      a
      Certificate of Designations, Preferences and Rights of Series A Convertible
      Preferred Stock of Matritech, Inc. (the “Certificate”) was filed with the
      Secretary of State of Delaware on March 4, 2005;

    

    3. 
That
      pursuant to the provisions of Section 9 of the Certificate, the Certificate
      was
      previously amended on January 13, 2006; and 

    

    4. 
That
      pursuant to the provisions of Section 9 of the Certificate, the Corporation
      and
      the holders of at least 75% of the outstanding Series A Preferred Stock have
      consented in writing to further amend the Certificate as follows:

    

    To
      delete
      subsection (c) of Section 6 in its entirety and substitute in place thereof
      the
      following:

    

    “(c) incur,
      assume or suffer to exist any indebtedness for borrowed money in excess of
      $12,000,000 in the aggregate, other than indebtedness incurred pursuant to
      a
      receivable or equipment lease financing and indebtedness outstanding on March
      4,
      2005 which has not been subsequently amended to increase the amount of
      indebtedness or the interest rate applicable thereto;”

    
 

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, said Matritech, Inc. has caused this Amendment to be signed
      by
      Stephen D. Chubb, its Chief Executive Officer, this 19th day of January,
      2007.

    

    

    MATRITECH,
      INC.

    

    

    By:
      ________________________ 

    Name:
      Stephen D. Chubb

    Title:
      Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]